Critical Path Institute

Critical Path Institute leads collaborations that accelerate drug development, advancing better treatments for people worldwide.

C-Path is an indispensable partner of excellence in medical development worldwide, shaping innovative scientific and regulatory pathways to accelerate delivery of therapies for patients in need.

The Problem
It takes too long and costs too much to take a new compound discovered in the laboratory through the drug development process and achieve a regulatory-approved safe and effective therapy.

The Solution
C-Path forms collaborative work groups comprised of diverse stakeholders to identify specific barriers to developing a safe and effective therapy for a given disease, and then creates tools and solutions that help drug developers overcome those barriers.

The Impact
C-Path is responsible for:
Process improvements that contributed to the first new treatment and regimen for tuberculosis in more than 50 years.
The first-of-its kind imaging biomarker for polycystic kidney disease, which contributed to the first-ever drug to be approved to slow the progression of this disease.
The original computerized tool to transform clinical trial design in Alzheimer's disease to be endorsed by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Clinical outcome assessments that have optimized incorporation of the patient's voice in the evaluation of treatment efficacy for asthma, depression, irritable bowel syndrome, myelofibrosis and non-small cell lung cancer.
New approaches to research that have led to the regulatory endorsement of viable biomarkers in Alzheimer's disease, Parkinson's disease, type 1 diabetes, kidney disease and tuberculosis.

Our ongoing success is due to a combination of public and private belief in our vision - there are many patrons responsible for C-Path's formation. Most notably, the visionaries at the FDA and the University of Arizona. Founded in Tucson, Arizona, C-Path's success is rooted in the support provided by Science Foundation Arizona, Flinn Foundation and local businesses and private individuals in "The Old Pueblo."

Testimonials

"CPAD's data collection efforts have produced the best data source in the world for exploring predictive modeling and understanding how patient and trial design impact Alzheimer's drug development. This work helps us all do better and more efficient clinical trials." Lars Lau Raket, Principal, International Project Statistician, Novo Nordisk and Special Advisor to CPAD.

"Somewhere in the future, hopefully there's not a DMD community. Until that time, I hope that D-RSC becomes more well known, and that everybody knows what kind of work we're doing." Ryan Russell, Duchenne Muscular Dystrophy Advocate.

"This matters. Part of the reason why I have a kidney is to be able to live my life, and I want to be able to live it." Haley Jensen, Transplant Recipient and Advocate, Transplant Therapeutics Consortium